KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Acquisitions (2020 - 2025)

Historic Acquisitions for Gilead Sciences (GILD) over the last 9 years, with Q3 2025 value amounting to $167.0 million.

  • Gilead Sciences' Acquisitions fell 7070.18% to $167.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $536.0 million, marking a year-over-year decrease of 8937.35%. This contributed to the annual value of $4.8 billion for FY2024, which is 32013.89% up from last year.
  • As of Q3 2025, Gilead Sciences' Acquisitions stood at $167.0 million, which was down 7070.18% from $21.0 million recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Acquisitions registered a high of $4.0 billion during Q1 2024, and its lowest value of $21.0 million during Q2 2025.
  • Moreover, its 5-year median value for Acquisitions was $243.0 million (2023), whereas its average is $517.6 million.
  • Within the past 5 years, the most significant YoY rise in Gilead Sciences' Acquisitions was 189206.35% (2021), while the steepest drop was 9978.13% (2021).
  • Gilead Sciences' Acquisitions (Quarter) stood at $44.0 million in 2021, then skyrocketed by 395.45% to $218.0 million in 2022, then grew by 27.98% to $279.0 million in 2023, then tumbled by 73.12% to $75.0 million in 2024, then soared by 122.67% to $167.0 million in 2025.
  • Its last three reported values are $167.0 million in Q3 2025, $21.0 million for Q2 2025, and $273.0 million during Q1 2025.